New trials, publications, preprints and grants on this target, month by month.
Trial
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
15 Jan 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
1 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
[Reappraisal of the value of CD30 testing in the diagnosis and treatment of lymphoma].
8 Nov 2026· Zhonghua bing li xue za zhi = Chinese journal of pathology· PUBMED
Publication
Immunohistochemical and clonality analyses of CD30+MUM1+ nonepitheliotropic T/NK-cell lymphomas in digits of dogs.
26 Oct 2026· Veterinary pathology· PUBMED
Trial
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
1 Oct 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Long-term Follow-up of Third-generation Anti-CD30 CAR T-cell Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicenter, Phase I/II Trial.
1 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Recurrent Hypoglycemia and Hypercalcemia As Presenting Features of CD30-Positive Peripheral T-cell Lymphoma, Not Otherwise Specified.
1 Oct 2026· Cureus· PUBMED
Publication
Decreased cerebrospinal fluid TNFRSF8 (sCD30) confirmed as a biomarker of Huntington's disease progression.
12 Sept 2026· Journal of neurology· PUBMED
Publication
CD30 expression in diffuse large B-cell lymphoma and primary mediastinal lymphoma: frequency, association with prognostic factors, and impact on survival.
5 Aug 2026· Hematology, transfusion and cell therapy· PUBMED
Publication
Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK-positive anaplastic large-cell lymphoma.
31 Jul 2026· Histopathology· PUBMED
Publication
Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.
8 Jun 2026· Journal of clinical medicine· PUBMED
Publication
Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.
27 Apr 2026· Cellular & molecular immunology· PUBMED
Publication
Type C Lymphomatoid Papulosis Following Immune Checkpoint Inhibition in a Melanoma Patient: A Reactive Mimicker of Cutaneous CD30+ Lymphoma.
1 Apr 2026· Dermatology practical & conceptual· PUBMED
Publication
CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production.
13 Mar 2026· BMC immunology· PUBMED
Publication
CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30+ lymphomas.
7 Mar 2026· Journal of translational medicine· PUBMED
Trial
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
4 Mar 2026· PHASE1 · RECRUITING· CTGOV
Publication
Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.
24 Feb 2026· Oncology research· PUBMED
Publication
Immune Checkpoint Activity and Prognostic Roles of TNFRSF8, CD160, and TNFSF9 in Primary and Brain Metastatic NSCLC.
22 Jan 2026· Asia-Pacific journal of clinical oncology· PUBMED
Publication
[Successful treatment of CD30-positive nodal follicular helper T-cell lymphoma, follicular type, with A-CHP and tucidinostat].
1 Jan 2026· [Rinsho ketsueki] The Japanese journal of clinical hematology· PUBMED
Publication
JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders.
1 Jan 2026· JAMA dermatology· PUBMED
Publication
A Case of Lymphomatoid Papulosis With CD15- and CD30-Positive Reed-Sternberg-Like Cells in CD8-Positive Mycosis Fungoides: Differential Diagnosis of Secondary Hodgkin Lymphoma and Large Cell Transformation of Mycosis Fungoides.
10 Dec 2025· Cureus· PUBMED
Publication
CD30+ T-cell lymphoma following Chimeric Antigen Receptor T-cell therapy (CART-cell therapy): Diagnostic uncertainty in a postimmunotherapy setting.
8 Nov 2025· JAAD case reports· PUBMED
Trial
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
27 Oct 2025· PHASE1 · RECRUITING· CTGOV
Trial
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
5 Sept 2025· NA · RECRUITING· CTGOV
Trial
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
1 Aug 2025· PHASE1_PHASE2 · TERMINATED· CTGOV
Trial
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
2 Jan 2025· PHASE1 · RECRUITING· CTIS
Publication
Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell lymphoma: a cell-of-origin- and microenvironment-dependent paradigm.
1 Jan 2025· Journal of clinical and experimental hematopathology : JCEH· PUBMED
Trial
Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma.
17 Dec 2024· PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING· CTIS